Fig. 7
From: Glycerol kinase 5 confers gefitinib resistance through SREBP1/SCD1 signaling pathway
SCD1 confers gefitinib resistance. a Western blotting on SCD1 expression in GK5-overexpressing (PC9-GK5) and control (PC9-Vector) PC9 cells. b RT-PCR on SCD1 expression in gefitinib-sensitive PC9 and gefitinib-resistant PC9R cells. * p < 0.05 vs. PC9 cells. c, d RT-PCR and Western blotting on SCD1 expression in SCD1-overexpressing (PC9-SCD1) and control (PC9-Vector) PC9 cells. * p < 0.05 vs. control. e CCK8 assay on cell viability of SCD1-overexpressing and control PC9 cells treated with gefitinib. *P < 0.05 vs. control. f, g RT-PCR and Western blot analysis of SCD1 expression in PC9R cells transfected with SCD1-shRNA (shSCD1) or negative control shRNA (shNEG). h Morphology of PC9R cells expressing shSCD1 or shNEG and cultured in the presence of 1 μM gefitinib. i CCK8 assay on cell viability of PC9R cells expressing shSCD1 or shNEG and treated with gefitinib. The data are representative of three similar experiments. * p < 0.05 vs. shNEG. j CCK8 assay on cell viability of PC9R cells treated with SCD1 inhibitor A939572. k, l RT-PCR and Western blot on SCD1 expression in SCD1-overexpressing (PC9R-SCD1) and control (PC9R-Vector) PC9R cells. * p < 0.05 vs. control. m CCK8 assay on cell proliferation of PC9R cells overexpressing SCD1 and infected with viral particles expressing shGK5–1 and shNEG. * p < 0.05 vs. shNEG